Tranilast inhibits vascular smooth muscle cell growth and intimal hyperplasia by induction of p21(waf1/cip1/sdi1) and p53

Circulation Research

Volumn 84, Issue 5, 1999, Pages 543-550

  Takahashi, Akihiro ^a   Taniguchi, Takahiro ^a   Ishikawa, Yuichi ^b   Yokoyama, Mitsuhiro ^a  

^a KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Faculty of Engineering   (Japan)

Author keywords

Angioplasty; Carotid arteries; Restenosis; Signal transduction; Smooth muscle

Indexed keywords

CYCLIN D2; CYCLIN DEPENDENT KINASE; CYCLIN E; PLATELET DERIVED GROWTH FACTOR; PROTEIN P21; PROTEIN P53; TRANILAST;

ANGIOPLASTY; ANIMAL CELL; ANIMAL EXPERIMENT; ARTERY INTIMA PROLIFERATION; ARTICLE; CELL GROWTH; CELL MIGRATION; CONTROLLED STUDY; ENZYME ASSAY; GROWTH INHIBITION; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INTIMA; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; RAT; RESTENOSIS; SIGNAL TRANSDUCTION; VASCULAR SMOOTH MUSCLE;

EID: 0033582960     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.84.5.543     Document Type: Article

References (37)

1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-809.
2. 1/S cell-cycle checkpoint in eukaryotic cells. Biochim Biophys Acta. 1994;1198:215-230.
3. Grana X, Reddy EP. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene. 1995;11:211-219.
4. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell. 1995;81:323-330.
5. 1 phase progression: cycling on cue. Cell. 1994;79:551-555.
6. Guadagno TM, Newport JW. Cdk2 kinase is required for entry into mitosis as a positive regulator of Cdc2-cyclin B kinase activity. Cell. 1996;84:73-82.
7. Matsushime H, Quelle DE, Shurtleff SA, Shibuya M, Sherr CJ, Kato JY. D-type cyclin-dependent kinase activity in mammalian cells. Mol Cell Biol. 1994;14:2066-2076.
8. Hunter T, Pines J. Cyclins and cancer, II: cyclin D and CDK inhibitors come of age. Cell. 1994;79:573-582.
9. Morgan DO. Principles of CDK regulation. Nature. 1995;374:131-134.
10. Gu Y, Turck CW, Morgan DO. Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Nature. 1993;366:707-710.
11. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 1993;75:805-816.
12. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature. 1993;366:701-704.
13. Macleod KF, Sherry N, Hannon G, Beach D, Tokino T, Kinzler K, Vogelstein B, Jacks T. p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev. 1995; 9:935-944.
14. Datto MB, Li Y, Panus JF, Howe DJ, Xiong Y, Wang XF. Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc Natl Acad Sci U S A. 1995; 92:5545-5549.
15. Gorospe M, Liu Y, Xu Q, Chrest FJ, Holbrook NJ. Inhibition of G1 cyclin-dependent kinase activity during growth arrest of human breast carcinoma cells by prostaglandin A2. Mol Cell Biol. 1996;16:762-770.
16. Zhang H, Hannon GJ, Beach D. p21-containing cyclin kinases exist in both active and inactive states. Genes Dev. 1994;8:1750-1758.
17. Noda A, Ning Y, Venable SF, Pereira-Smith OM, Smith JR. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res. 1994;211:90-98.
18. Azuma H, Banno K, Yoshimura T. Pharmacological properties of N-(3′,4′-dimethoxycinnamoyl) anthranilic acid (N-5′), a new anti-atopic agent. Br J Pharmacol. 1976;58:483-488.
19. Ikeda H, Inao M, Fujiwara K. Inhibitory effect of tranilast on activation and transforming growth factor beta 1 expression in cultured rat stellate cells. Biochem Biophys Res Commun. 1996;227:322-327.
20. Fukuyama J, Miyazawa K, Hamano S, Ujiie A. Inhibitory effects of tranilast on proliferation, migration, and collagen synthesis of human vascular smooth muscle cells. Can J Physiol Pharmacol. 1996;74: 80-84.
21. The TREAT Study Investigation. The impact of tranilast on restenosis following coronary angioplasty: The Tranilast Restenosis Following Angioplasty Trial (TREAT). Circulation. 1994;90(suppl I):I-652. Abstract.
22. Miyazawa K, Fukuyama J, Misawa K, Hamano S, Ujiie A. Tranilast antagonizes angiotensin II and inhibits its biological effects in vascular smooth muscle cells. Atherosclerosis. 1996;121:167-173.
23. Hishikawa K, Nakaki T, Hirahashi J, Marumo T, Saruta T. Tranilast inhibits the effects of platelet-derived growth factor on cell proliferation and induction of nitric oxide. Eur J Pharmacol. 1995;291:435-438.
24. Nie L, Mogami H, Kanzaki M, Shibata H, Kojima I. Blockade of DNA synthesis induced by platelet-derived growth factor by tranilast, an inhibitor of calcium entry, in vascular smooth muscle cells. Mol Pharmacol. 1996;50:763-769.
25. Kikuchi S, Umemura K, Kondo K, Nakashima M. Tranilast suppresses intimai hyperplasia after photochemically induced endothelial injury in the rat. Eur J Pharmacol. 1996;295:221-227.
26. Gunther S, Alexander RW, Atkinson WJ, Gimbrone M Jr. Functional angiotensin II receptors in cultured vascular smooth muscle cells. J Cell Biol. 1982;92:289-298.
27. Takahashi A, Taniguchi T, Fujioka Y, Ishikawa Y, Yokoyama M. Effects of lipoprotein(a) and low density lipoprotein on growth of mitogen-stimulated human umbilical vein endothelial cells. Atherosclerosis. 1996; 120:93-99.
28. Clowes AW, Reidy MA, Clowes MM. Kinetics of cellular proliferation after arterial injury. I. Smooth muscle growth in the absence of endothelium. Lab Invest. 1983;49:327-333.
29. Gu Y, Rosenblatt J, Morgan DO. Cell cycle regulation of CDK2 activity by phosphorylation of Thr160 and Tyr15. EMBO J. 1992;11:3995-4005.
30. Yang ZY, Simari RD, Perkins ND, San H, Gordon D, Nabel GJ, Nabel EG. Role of the p21 cyclin-dependent kinase inhibitor in limiting intimal cell proliferation in response to arterial injury. Proc Natl Acad Sci U S A. 1996;93:7905-7910.
31. Knudsen ES, Wang JY. Differential regulation of retinoblastoma protein function by specific Cdk phosphorylation sites. J Biol Chem. 1996;271: 8313-8320.
32. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell. 1993;75:817-825.
33. Lundberg AS, Weinberg RA. Functional inactivation of the retino-blastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol Cell Biol. 1998;18:753-761.
34. Wei GL, Krasinski K, Keamey M, Isner JM, Walsh K, Andres V. Temporally and spatially coordinated expression of cell cycle regulatory factors after angioplasty. Circ Res. 1997;80:418-426.
35. Tanner FC, Yang ZY, Duckers E, Gordon D, Nabel GJ, Nabel EG. Expression of cyclin-dependent kinase inhibitors in vascular disease. Circ Res. 1998;82:396-403.
36. Chang MW, Barr E, Lu MM, Barton K, Leiden JM. Adenovirus-mediated over-expression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. J Clin Invest. 1995;96:2260-2268.
37. Clowes AW, Clowes MM, Reidy MA. Kinetics of cellular proliferation after arterial injury. III. Endothelial and smooth muscle growth in chronically denuded vessels. Lab Invest. 1986;54:295-303.